SCHEMBL25845322

SCHEMBL25845322

CCC1CN(C(=O)OC(C)(C)C)CC1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.44
DDB1 Q16531 2/20 0.40
CRBN Q96SW2 2/20 0.40
NAMPT P43490 1/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
KMT2A Q03164 1/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
ESR2 Q92731 1/20 0.36
PREP P48147 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8255912 0.86 NR1H2 (0.43) NR1H2DDB1CRBNNAMPTMAPT
SCHEMBL2732461 0.85 NR1H2 (0.40) NR1H2DDB1CRBNNAMPTMAPT
SCHEMBL656014 0.85 DDB1 (0.44) NR1H2DDB1CRBNMAPTMEN1
SCHEMBL12356486 0.85 KDM4E (0.45) DDB1CRBNMAPTMEN1ALDH1A1
SCHEMBL19420074 0.85 KDM4E (0.45) DDB1CRBNMAPTMEN1ALDH1A1
SCHEMBL28405005 0.84 NR1H2 (0.41) NR1H2DDB1CRBNNAMPTMAPT
SCHEMBL16568475 0.82 NR1H2 (0.40) NR1H2DDB1CRBNNAMPTMAPT
SCHEMBL2723574 0.82 NR1H2 (0.40) NR1H2DDB1CRBNNAMPTMAPT
SCHEMBL31424868 0.82 MEN1 (0.45) NR1H2DDB1CRBNMAPTMEN1
SCHEMBL29737454 0.82 NR1H2 (0.40) NR1H2DDB1CRBNNAMPTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20230303531-A1 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME TREVENA, INC. 2023-09-28 US disclosed
US-11702408-B2 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same TREVENA, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702408-B2 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same OPRD1, OPRM1, OPRK1 NR1H2 202/4885DDB1 2780/4885CRBN 1815/4885
US-20230303531-A1 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME OPRD1, OPRM1, OPRK1 NR1H2 244/4885DDB1 2793/4885CRBN 1644/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A NR1H2 1135/4885DDB1 2862/4885CRBN 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.